Board summary
Key figures
35,526
Registered population
60.4% aged 18–64
20.3%
Aged 65+
ICB 19.0% · England 17.9%
7.4%
Ethnic minority (non-White)
3.4% Asian · England 9.6%
23.1%
In IMD quintile 1
ICB 31.9% · England 21.0%
~6,413
Core20 residents (est.)
Resident basis; registered basis ~6,849 · see page 3
5,204
Hypertension register
+6.01% in 3 yrs · England +5.60%
381
SMI register
10.1% of Cheshire West and Chester (LAD)'s
805
COPD register
Reviews -4.91% in 3 yrs
Forecast to 2030
5,975
Hypertension patients, 2030
+771 on today
76.0%
QRISK ≥20% on statins, 2030
+4.32pp over 3 yrs
4.9%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma annual reviews trail comparators after falling.
Asthma reviews reached 58.9% (England 65.7%), falling 7.3% over 2023 to 2025 (England +4.4%) and leaving about 980 of 2,394 patients unreviewed.
Hypertension BP control and recorded prevalence lag.
Hypertension treatment to target is 67.4% (England 70.3%, borough 68.9%), while 14.5% recorded prevalence leaves an unadjusted +207 to +824 benchmark gap.
Non-frail diabetes HbA1c and statin therapy lead.
Non-frail diabetes HbA1c control reached 59.5% (+18.2% over 2023 to 2025 vs England +4.4%), alongside 66.4% statin therapy for QRISK >= 20%.
Population, age and ethnicity
Older adults represent 20.3% of patients, alongside 23 care homes and 985 beds
Across 35,526 registered patients, 20.3% (7,226) are aged 65+, matching Cheshire West and Chester (LAD) (20.3%) but above NHS Cheshire and Merseyside ICB (19.0%) and England (17.9%). Children aged 0–17 comprise 19.2% (LAD 18.5%, ICB 19.2%, England 19.6%). Based on Census usual residents rather than registered patients, 92.6% are White (LAD 95.3%, ICB 93.0%, England 81.1%) and 7.4% are from ethnic minority groups, including Asian residents at 3.4% (LAD 2.0%, ICB 2.8%, England 9.6%). List size is projected to grow 2.1% to 2030 (LAD 2.5%, ICB 2.3%, England 2.3%) under unverified methodology.
Age profile
65+: ICB 19.0%, England 17.9%
Ethnicity
Older people · falls rows are Cheshire West and Chester (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Cheshire West and Chester LA) | 2,109 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 80.7% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 59.5% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Cheshire West and Chester LA) | 893 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Cheshire West and Chester LA) | 14.9 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Deprivation is moderate overall but sharply concentrated, spanning a 69.9 percentage-point practice spread
The PCN Core20 cohort is 23.1%, above Cheshire West and Chester (15.7%) and England (21.0%), but below the ICB (31.9%), alongside an average IMD decile of 6.0. Deprivation is sharply polarised: Western Ave Medical Ctre has a 69.9% Core20 share (an estimated 3,379 patients), whereas The Handbridge Med.ctr. records 0.0%. City Walls Medical Centre holds substantial volume (estimated 2,544 patients; 17.4% share). A 3.78 percentage-point reconciliation discrepancy between the PCN rate (23.1%) and weighted practice share (19.3%) requires verification before setting allocation formulas.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
381
SMI register
1.06% recorded prevalence
150
Learning disability register
0.42% recorded prevalence
23
Care homes, 985 beds
In the PCN catchment
9.6%
Provide unpaid care
Cheshire West and Chester (LAD), Census 2021
The catchment includes 23 care homes (985 beds). Severe mental illness prevalence is 1.1% (381 patients; LAD 1.0%, ICB 1.1%, England 1.0%). Learning disability prevalence is 0.4% (150 patients), trailing Cheshire West and Chester (LAD) (0.5%), NHS Cheshire and Merseyside Integrated Care Board (0.6%) and England (0.6%).
Severe mental illness: physical health checks
SMI health checks trail England: recorded BMI is 72.8% (England 82.1%), blood pressure is 79.1% (England 83.4%) and alcohol status is 70.7% (England 81.8%). At City Walls Medical Centre, recorded BMI is 63.2% and blood pressure is 73.1%.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
5,204
Hypertension register
+6.01%
Register growth, 3 yrs
Cheshire West and Chester (LAD) +6.60% · England +5.60%
+1.98pp
BP control, under 80
≤140/90 · +0.30pp aged 80+
+771
More patients by 2030
Forecast 5,975 (16.31%)
Hypertension case-finding and control
Hypertension recorded prevalence is 14.5% (5,204 patients), trailing Cheshire West and Chester (LAD) at 17.0%, the ICB at 16.8% and England at 15.2%, though this crude figure is not age-adjusted. While recent blood pressure recording reaches 89.6% (England 90.0%), treatment to threshold is 67.4% (England 70.3%, borough 68.9%, ICB 69.1%). Control for patients aged under 80 is 64.4% (England 67.8%), dropping to 52.8% at City Walls Medical Centre, while control for those aged 80+ is 76.9% (England 81.2%). Blood pressure treatment to threshold trails all benchmarks despite strong recording reach, so prioritizing medication titration and clinical review for uncontrolled hypertensive patients is the primary operational need.
Lipids and statins
Lipid-lowering therapy reaches 66.4% of patients with QRISK ≥ 20% (England 63.6%, borough 63.8%), 77.0% in diabetes without CVD (England 73.2%) and 74.0% in chronic kidney disease (England 70.3%). With coverage exceeding comparators across high-risk groups, the PCN should sustain its current systematic identification and prescribing pathways.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 59,377 | £1.30 | £1.71 | £1.86 | £77,190 |
| Cardiovascular (all), 2025 | 80,059 | £4.89 | £4.37 | £3.33 | £391,489 |
In 2026, the PCN prescribed 59,377 items for lipid-regulating drugs at £1.30 per item, below Cheshire West and Chester (LAD) (£1.44), the ICB (£1.71) and England (£1.86), spending £33,251 less than at England's unit cost across 59,377 items. Lower unit costs than comparators may reflect favorable formulary choices, showing an opportunity to sustain cost-effective prescribing.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−7.30%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−0.23%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 7.1% (2,394 patients), but reviews fell 7.3% over 2023 to 2025 to 58.9% (England +4.4%, current 65.7%), leaving about 980 patients unreviewed. COPD reviews fell 4.9% over 2023 to 2025 to 63.4% (England +2.8%, current 76.4%). Second-hand smoke status recording for asthma patients aged 6-19 is 68.1% (England 78.8%), while youth asthma prescribing is 1,905 items per 1,000 aged 5-19 (England 1,488). Lagging reviews may leave high inhaler users unmonitored; QOF denominators include personalised care adjustments.
Cancer register and children's immunisation
Cancer prevalence is 4.2% (1,499 patients; England 3.8%). In childhood immunisation, 6-in-1 coverage at 12 months reached 97.0% (cohort 67, Q1 2025/26), exceeding the 95.0% target. However, age-5 MMR dose 2 and the 4-in-1 booster are both 86.8% (cohort 91), falling 8.2 pp below target. In this age-5 cohort, MMR dose 2 trails dose 1 (93.4%) by 6.6 pp; at Lache Health Centre, the drop is 23.1 pp.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.5%
Cheshire and Merseyside ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,640
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Cheshire and Merseyside ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 11% | 2,354 |
| Breast | 87.1% | 85.4% | 11% | 2,083 |
| Prostate | 52.3% | 53.2% | 12% | 2,037 |
| Bowel | 44.9% | 47.0% | 16% | 1,674 |
| Skin cancer | 86.9% | 87.8% | 21% | 932 |
Across NHS Cheshire and Merseyside ICB in 2022, 55.5% of cancers with a known stage (7,482 of 13,490) were diagnosed at stage 1 or 2, in line with England (55.3%) but 19.5 pp below the 75.0% national ambition by 2028. Known-stage share was 72.8% (13,490 of 18,522 registered cancers). Early-stage detection reached 87.1% for breast and 40.4% for lung, but was 44.9% for bowel. These system figures do not establish PCN-level staging. Between 2023 and 2025, PCN cancer register growth was +7.9% (England +9.0%, ICB +9.3%), with Lache Health Centre at +3.7% and The Handbridge Med.ctr. at +3.9%. Auditing practice-level referral variation could uncover diagnostic safety-netting opportunities.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026 (provisional), Countess of Chester Hospital NHS Foundation Trust achieved 87.4% on the cancer 28-day faster diagnosis standard (standard 75.0%), above North Cheshire and Mersey NHS Foundation Trust (80.2%), England (79.3%), NHS Cheshire and Merseyside Integrated Care Board (77.2%) and Wirral University Teaching Hospital NHS Foundation Trust (74.7%). On the 62-day standard, Countess of Chester Hospital NHS Foundation Trust reached 83.3% (standard 85.0%), below North Cheshire and Mersey NHS Foundation Trust (83.7%) but above Wirral University Teaching Hospital NHS Foundation Trust (77.6%), the ICB (76.2%) and England (71.2%). Secondary diagnostic timeliness broadly supports rapid cancer assessment for referred.
| Pathways within standard (%) | Countess of Chester | North Cheshire and Mersey | Wirral | Cheshire and Merseyside ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 87.37 | 80.21 | 74.71 | 77.25 | 79.32 |
| 31-day treatment (96%) | 93.48 | 98.17 | 92.53 | 95.71 | 92.50 |
| 62-day referral to treatment (85%) | 83.28 | 83.67 | 77.65 | 76.23 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Countess of Chester | North Cheshire and Mersey | Wirral | England |
|---|---|---|---|---|
| MRI | 11.26 | 0.53 | 1.54 | 21.40 |
| CT | 4.18 | 2.32 | 1.55 | 9.92 |
| Echocardiography | 31.44 | 28.04 | 5.07 | 28.48 |
| Colonoscopy | 26.44 | 15.98 | 32.81 | 30.83 |
| Gastroscopy | 27.52 | 20.24 | 17.73 | 29.02 |
| All 15 DM01 tests | 20.16 | 6.34 | 5.02 | 23.14 |
| Community services activity | Cheshire West and Chester residents | Cheshire and Merseyside ICB |
|---|---|---|
| Care contacts | 47,655 | 541,280 |
| Referrals | 10,325 | 97,150 |
| Patients with a contact | 18,585 | 146,240 |
Community services (residents of Cheshire West and Chester), Jun 2026 (provisional). In June 2026 (provisional), community health service contacts with adults aged 65+ accounted for 52.7% of all contacts for Cheshire West and Chester residents (25,095 of 47,655). Primary care cancer safety-netting should coordinate closely with community teams supporting older residents.
Practice variation and patient experience
Patient experience varies by 25.5 pp, while practice vaccination achievement spans 36.4 pp
Across 2025/26 QOF domains, clinical achievement reached 100.0% at City Walls Medical Centre, 99.4% at Western Ave Medical Ctre, 99.3% at The Handbridge Med.ctr., and 91.7% at Lache Health Centre (England 97.1%). However, vaccination achievement spans a 36.4 pp range, from 52.0% at Lache Health Centre to 15.6% at Western Ave Medical Ctre.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Western Ave | 106 | 69.9 | 80.1% | 78.9% | 93.0% |
| Lache | 101 | 11.3 | 60.0% | 85.9% | 86.3% |
| Handbridge | 120 | 0.0 | 59.7% | 63.5% | 82.5% |
| City Walls | 106 | 17.4 | 45.3% | 60.9% | 67.6% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
18 of 25 tracked measures trailed England's three-year change despite strong diabetes control
Across 25 tracked measures, 18 trailed England's three-year change. Annual reviews over 2023 to 2025 fell for heart failure by 5.0% to 65.0% (England +8.7%), asthma by 7.3% to 58.9% (England +4.4%), and COPD by 4.9% to 63.4% (England +2.8%). Learning disability register prevalence fell 4.8% to 0.4% (England +5.4%), and severe mental illness BMI checks fell 1.0 pp to 72.8% (England +5.1 pp). In contrast, non-frail diabetes HbA1c control rose +18.2% to 59.5% (England +4.4%), and breast screening rose +13.6% to 77.2% (England +8.4%).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
Asthma reviews
Learning disability register
COPD reviews
BMI record (SMI)
Diabetes HbA1c control
Breast screening (53-70)
QRISK statin treatment
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Cheshire West and Chester (LAD) | Asset | PCN | Cheshire West and Chester (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 23 (985 beds) | n/a | Schools (catchment) | 76 | n/a |
| Children's centres | 4 | 15 | Places of worship | 66 | 231 |
| Libraries | 3 | 16 | Food banks (VCS) | n/a | 1 |
| Homelessness support (VCS) | n/a | 1 | Day centres (VCS) | n/a | 1 |
| Carers support groups (VCS) | n/a | 1 | Primary schools (LA maintained) | 13 | 70 |
| Primary academies | 8 | 46 | Special schools | n/a | 5 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma review and inhaler recall
Asthma annual review coverage is 58.9% (LAD 60.0%, ICB 62.3%, England 65.7%), falling 7.3% over 2023 to 2025 (England +4.4%), leaving 984 (about 980) of 2,394 patients unreviewed. For discussion: practices could run a single-template asthma recall prioritising repeat inhaler users and after-school slots. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Hypertension case-finding and pharmacist titration
Hypertension prevalence is 14.5% (5,204 patients) vs England 15.2% and LAD 17.0% (unadjusted gap +207 to +824 on the 35,526 list). Treatment to target is 67.4% (England 70.3%), and 52.8% for under-80s at City Walls Medical Centre. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 3
Care-home and older-adult dementia case-finding
Dementia prevalence is 0.6% (219 patients), trailing England (0.8%), ICB (0.9%) and LAD (1.0%), with +0.4% growth over 2023 to 2025 (England +6.0%, LAD +8.6%), giving an unadjusted gap of +59 to +126 across 35,526 patients. Moderate effort to run.
Evidence base: dementia diagnosis rates lag in deprived and minority ethnic populations and in care homes; the register is the cohort for diagnosis-rate improvement and the annual dementia review, and diagnosis and post-diagnostic support delay care-home entry.
Policy anchor: national dementia diagnosis-rate ambition of 66.7%; 95% of people with complex needs to have an agreed care plan by 2027.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Proactive older adult review (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Targeted Core20 outreach and reconciliation (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical check recall (p4) | SMI register with a BMI recorded in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension titration review (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cancer referral and register audit (p7) | Cancer: QOF prevalence | Core20PLUS5, 75% stage 1–2 by 2028 | PCN |
| Practice telephony and triage review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Structured asthma review and inhaler recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Patients with Asthma (6-19 yrs): Second-hand smoking status recorded in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Hypertension case-finding and pharmacist titration (p12) | Registered population · Aged 65+ · Hypertension register | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN & Practice |
| Option 3 · Care-home and older-adult dementia case-finding (p12) | Registered population · Aged 65+ · Count of Care Homes in PCN catchment | 66.7% diagnosis ambition · 95% care plan 2027 | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
